ClinicalTrials.gg
CompletedNCT00370292Updated Oct 20, 2009Results posted

Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Pemetrexed - Before Protocol Amendment and Pemetrexed - After Protocol Amendment in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
173rd of 223
19 · median 64
Started
2006
with 24 others
Phase 2
128 of 227
12 open now
Registered
39th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 173rd largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 39th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles. Pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action. Purpose of the trial is to monitor the blood values of these biomolecules at different time intervals, to optimize the synergism between pemetrexed and gemcitabine.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven IIIB and IV NSCLC.
  • No symptomatic uncontrolled
  • Not suitable for platinum containing regimens if chemo-naive
  • Performance status less than or equal to 2 on the (ECOG) Scale.
  • (CrCl) greater than or equal to 45 milliliters per min (mL/min)

Exclusion criteria

Exclusion Criteria

  • Prior radiation to greater than 25% of bone marrow
  • Inability to interrupt Aspirin at doses of greater than 1.3 grams/day or non-steroidal anti-inflammatory agents for a 5-day period.
  • Presence of third-space fluid collections not controllable.
  • Significant cardiac disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Pemetrexed - Before Protocol Amendment

    Drug: Pemetrexed - Before Protocol Amendment

  • Experimental
    Pemetrexed - After Protocol Amendment

    Drug: Pemetrexed - After Protocol Amendment

Interventions

  • 500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue

    Also known as: LY231514, Alimta

  • 500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.

    Also known as: LY231514, Alimta

06

What researchers measure

Primary outcomes

  1. Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3

    dCK and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

    Time frame: pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)

  2. Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3

    dCK (see Outcome #1)and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

    Time frame: pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)

Secondary outcomes

  1. Best Objective Tumor Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to measured response (every 14 days for 6 cycles)

07

Results

Posted Oct 12, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started19
Completed6
Not completed13
Withdrew: Disease progression4
Withdrew: Adverse event7
Withdrew: Physician decision2

Outcome measures

PrimaryMean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3

dCK and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Time frame:
pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)
Reported as:
Mean · mRNA relative values (ratio with GAPDH)
Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3
mRNA relative values (ratio with GAPDH)dCK - Cycle 1dCK - Cycle 2dCK - Cycle 3
Pre-Dose0.92 ± 0.030.92 ± 0.030.92 ± 0.02
1 Hour Post-Dose0.96 ± 0.040.95 ± 0.030.96 ± 0.03
2 Hours Post-Dose0.96 ± 0.040.96 ± 0.040.97 ± 0.02
4 Hours Post-Dose0.93 ± 0.040.94 ± 0.040.92 ± 0.03
6 Hours Post-Dose0.92 ± 0.030.91 ± 0.040.91 ± 0.03
24 Hours Post-Dose0.96 ± 0.040.97 ± 0.030.96 ± 0.03
48 Hours Post-Dose0.97 ± 0.040.96 ± 0.040.97 ± 0.03
Statistical analysis
  • dCK - Cycle 1 vs dCK - Cycle 2 vs dCK - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 1 Hour Post-Dose (1 hour across cycles compared with pre-dose across cycles).)
  • dCK - Cycle 1 vs dCK - Cycle 2 vs dCK - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 2 Hours Post-Dose (2 hours across cycles compared with pre-dose across cycles).)
  • dCK - Cycle 1 vs dCK - Cycle 2 vs dCK - Cycle 3 · Repeated Measures Analysis of Variance · p = 0.030 (P-value for 4 Hours Post-Dose (4 hours across cycles compared with pre-dose across cycles).)
  • dCK - Cycle 1 vs dCK - Cycle 2 vs dCK - Cycle 3 · Repeated Measures Analysis of Variance · p = 0.166 (P-value for 6 Hours Post-Dose (6 hours across cycles compared with pre-dose across cycles).)
  • dCK - Cycle 1 vs dCK - Cycle 2 vs dCK - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 24 Hours Post-Dose (24 hours across cycles compared with pre-dose across cycles).)
  • dCK - Cycle 1 vs dCK - Cycle 2 vs dCK - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 48 Hours Post-Dose (48 hours across cycles compared with pre-dose across cycles).)
SecondaryBest Objective Tumor Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to measured response (every 14 days for 6 cycles)
Reported as:
Number · participants
Best Objective Tumor Response
participantsPemetrexed - Before AmendmentPemetrexed - After Amendment
Partial Response10
Stable Disease24
Progressive Disease30
Early Death10
Unconfirmed Stable Disease53
PrimaryMean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3

dCK (see Outcome #1)and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Time frame:
pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)
Reported as:
Mean · mRNA relative values (ratio with GAPDH)
Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3
mRNA relative values (ratio with GAPDH)hENT - Cycle 1hENT - Cycle 2hENT - Cycle 3
Pre-Dose0.86 ± 0.030.86 ± 0.030.87 ± 0.02
1 Hour Post-Dose0.88 ± 0.040.89 ± 0.040.90 ± 0.03
2 Hours Post-Dose0.88 ± 0.040.90 ± 0.040.90 ± 0.04
4 Hours Post-Dose0.86 ± 0.040.88 ± 0.050.86 ± 0.03
6 Hours Post-Dose0.86 ± 0.040.86 ± 0.040.86 ± 0.02
24 Hours Post-Dose0.89 ± 0.040.91 ± 0.040.91 ± 0.02
48 Hours Post-Dose0.90 ± 0.040.91 ± 0.040.91 ± 0.02
Statistical analysis
  • hENT - Cycle 1 vs hENT - Cycle 2 vs hENT - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 1 Hour Post-Dose (1 hour across cycles compared with pre-dose across cycles).)
  • hENT - Cycle 1 vs hENT - Cycle 2 vs hENT - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 2 Hours Post-Dose (2 hours across cycles compared with pre-dose across cycles).)
  • hENT - Cycle 1 vs hENT - Cycle 2 vs hENT - Cycle 3 · Repeated Measures Analysis of Variance · p = 0.333 (P-value for 4 Hours Post-Dose (4 hours across cycles compared with pre-dose across cycles).)
  • hENT - Cycle 1 vs hENT - Cycle 2 vs hENT - Cycle 3 · Repeated Measures Analysis of Variance · p = 0.849 (P-value for 6 Hours Post-Dose (6 hours across cycles compared with pre-dose across cycles).)
  • hENT - Cycle 1 vs hENT - Cycle 2 vs hENT - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 24 Hours Post-Dose (24 hours across cycles compared with pre-dose across cycles).)
  • hENT - Cycle 1 vs hENT - Cycle 2 vs hENT - Cycle 3 · Repeated Measures Analysis of Variance · p = <0.001 (P-value for 48 Hours Post-Dose (48 hours across cycles compared with pre-dose across cycles).)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—5/19 (26.3%)19/19 (100%)
Most frequent serious events
Most frequent serious events
EventPemetrexed
ThrombocytopeniaBlood and lymphatic system disorders1/19
Cardiac arrestCardiac disorders1/19
Disease progressionGeneral disorders1/19
Renal colicRenal and urinary disorders1/19
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/19
Respiratory failureRespiratory, thoracic and mediastinal disorders1/19
HaemorrhageVascular disorders1/19
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPemetrexed
PyrexiaGeneral disorders14/19
AstheniaGeneral disorders9/19
Mucosal inflammationGeneral disorders8/19
DyspnoeaRespiratory, thoracic and mediastinal disorders7/19
ConjunctivitisEye disorders6/19
ConstipationGastrointestinal disorders6/19
AnaemiaBlood and lymphatic system disorders5/19
DiarrhoeaGastrointestinal disorders5/19
CoughRespiratory, thoracic and mediastinal disorders5/19
FatigueGeneral disorders4/19

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
Mean69.1 ± 10.3469.4 ± 6.4569.2 ± 8.90
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
Female358
Male9211
Region of Enrollment
Region of Enrollment(participants)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
Italy12719
Disease Stages
Disease Stages(participants)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
Not Known011
Stage IA202
Stage IB101
Stage IIA101
Stage IIB011
Stage IIIA011
Stage IIIB325
Stage IV527
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
0 - Fully Active415
1 - Ambulatory, Restricted Strenuous Activity6511
2 - Ambulatory, No Work Activities213
Histopathological Grade
Histopathological Grade(participants)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
Not Done729
G1 - Well-Differentiated112
G2 - Moderately Differentiated213
G3 - Poorly Differentiated235
Previous Anti-Tumor Treatment
Previous Anti-Tumor Treatment(participants)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
No516
Yes7613
Previous Surgery
Previous Surgery(participants)Pemetrexed - Before AmendmentPemetrexed - After AmendmentTotal
Surgery - No415
Surgery - Yes: Pneumonectomy011
Surgery - Yes: Lobectomy336
Surgery - Yes: Other538
Surgery - Yes: Radical549

8 further baseline measures are reported on the registry.

08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2006
First posted
Aug 31, 2006
Start
Sep 2006
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Oct 12, 2009
Last update
Oct 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00370292
First posted
Aug 31, 2006
Start date
Sep 2006
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Oct 12, 2009
Last update
Oct 20, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion